Quantcast
Home > Quotes > CKPT

Checkpoint Therapeutics, Inc. Common Stock (CKPT) Quote & Summary Data

CKPT 
$2.02
*  
0.11
5.16%
Get CKPT Alerts
*Delayed - data as of Dec. 12, 2018  -  Find a broker to begin trading CKPT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CKPT Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
15.5
Today's High / Low
$ 2.1937 / $ 2.02
Share Volume
21,127
50 Day Avg. Daily Volume
49,284
Previous Close
$ 2.13
52 Week High / Low
$ 6.29 / $ 1.8907
Market Cap
64,857,885
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.02

Intraday Chart

Shares Traded

Share Volume:
21,127
50 Day Avg. Daily Volume:
49,284

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.16

Trading Range

The current last sale of $2.02 is 6.84% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.1937 $ 6.29
 Low: $ 2.02 $ 1.8907

Company Description (as filed with the SEC)

We are a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Our lead product candidate is a fully-human monoclonal antibody licensed from the Dana-Farber Cancer Institute ("Dana-Farber") that targets programmed death-ligand 1 ("PD-L1"). We commenced a Phase 1 clinical study for our anti-PD-L1 antibody, CK-301, in October 2017, evaluating the safety and tolerability of CK-301 in checkpoint therapy-na├»ve patients with selected recurrent or metastatic cancers, and plan to develop CK-301 as a treatment for patients with non-small cell lung cancer ("NSCLC") and other solid tumors. In addition, we are developing a small-molecule, targeted anti-cancer agent, CK-101, for the treatment of patients with epidermal growth factor receptor ("EGFR") mutation-positive NSCLC.  ... More ...  


Risk Grade

Where does CKPT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.10
Open Date:
Dec. 12, 2018
Close Price:
$ 2.05
Close Date:
Dec. 12, 2018

Consensus Recommendation

Analyst Info